Neumora Therapeutics (NMRA) Retained Earnings (2022 - 2026)

Neumora Therapeutics' Retained Earnings history runs 5 years deep, the most recent figure standing at -$1.2 billion for Q1 2026.

• In Q1 2026, Retained Earnings fell 21.91% year-over-year to -$1.2 billion; the TTM figure through Mar 2026 stood at -$1.2 billion (down 21.91% YoY), while the FY2025 annual figure was -$1.2 billion, down 25.01% from the prior year.
• Retained Earnings for Q1 2026 stood at -$1.2 billion, down from -$1.2 billion in the prior quarter.
• The five-year high for Retained Earnings was -$15000.0 in Q2 2025, with the low at -$1.2 billion in Q1 2026.
• The 5-year median for Retained Earnings is -$444.6 million (2022), against an average of -$533.2 million.
• The sharpest annual moves came in 2024 and 2025: Retained Earnings tumbled 1246243.42% in 2024, then jumped 91.98% in 2025.
• Neumora Therapeutics' Retained Earnings stood at -$774000.0 in 2022, then surged by 90.18% to -$76000.0 in 2023, then sank by 1246243.42% to -$947.2 million in 2024, then slipped by 25.01% to -$1.2 billion in 2025, then dropped by 4.51% to -$1.2 billion in 2026.
• Business Quant data shows NMRA's Retained Earnings at -$1.2 billion in Q1 2026, -$1.2 billion in Q4 2025, and -$1.1 billion in Q3 2025.